We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Fast Label-Free Method Identifies Aggressive Cancer Cells

By LabMedica International staff writers
Posted on 29 Jan 2026

Distinguishing aggressive cancer cells from less dangerous ones remains a major clinical challenge, as cells with high metastatic potential often appear similar under standard laboratory conditions. More...

Conventional genetic and molecular tests can be costly, time-consuming, and may fail to capture how likely a cancer is to spread. Metastasis depends not only on gene expression but also on how cancer cells physically interact with their surroundings. Now, a new study shows that aggressive cancer cells can be identified quickly and without labels by observing their physical behavior on specially designed surfaces.

Researchers at the Hebrew University of Jerusalem (Jerusalem, Israel) have developed engineered meta-surfaces patterned with microscopic, immobilized plastic particles that create nano- and micro-scale topographies. These textured surfaces act as mechanical probes, allowing researchers to observe how cancer cells interact physically with their environment.

When cancer cells are placed on these surfaces, they encounter a complex landscape rather than a flat plane. This setup reveals differences in cell adhesion, particle internalization, and shape adaptation. The approach is label-free, does not rely on genetic manipulation or chemical markers, and is compatible with standard imaging and laboratory workflows.

Using the patterned surfaces, the researchers found that aggressive cancer cells grip the surface more strongly, engulf significantly more particles, and stretch and wrap themselves around the microscopic features. Less aggressive cells showed far weaker adhesion and minimal shape changes, despite appearing similar on conventional flat culture surfaces. These functional differences were consistently detectable using the new method.

The study also showed that cells at different stages of metastasis could be distinguished based on their mechanical behavior. Cancer cells temporarily reduced adhesion after leaving the primary tumor and regained strong mechanical interactions upon reaching new sites. The findings, published in Materials Today Bio, demonstrate that cancer aggressiveness is a dynamic functional state rather than a fixed genetic identity.

Measuring how cells physically push, pull, and adhere provides insights into metastatic potential that molecular tests alone may miss. This approach offers a fast, low-cost way to identify high-risk cancer cells and better understand the mechanics of cancer spread. In the future, the technology could support rapid screening of tumor aggressiveness, metastasis research, drug testing, and personalized treatment strategies. Because the surfaces are simple to manufacture and integrate into existing workflows, the method has clear potential for translational and clinical research applications.

“Our work shows that how cancer cells push, pull, and grip their surroundings can tell us a great deal about how dangerous they are,” said Professor Ofra Benny from the School of Pharmacy at the Hebrew University. “This opens a new path for cancer diagnostics that is both powerful and surprisingly simple.”

Related Links:
Hebrew University of Jerusalem


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Drug Testing Assays
Atellica DT 250 Analyzer
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.